Estrogen receptor alpha (ER␣), a key driver of growth in the majority of breast cancers, contains an unstructured transactivation domain (AF1) in its N terminus that is a convergence point for growth factor and hormonal activation. This domain is controlled by phosphorylation, but how phosphorylation impacts AF1 structure and function is unclear. We found that serine 118 (S118) phosphorylation of the ER␣ AF1 region in response to estrogen (agonist), tamoxifen (antagonist), and growth factors results in recruitment of the peptidyl prolyl cis/trans isomerase Pin1. Phosphorylation of S118 is critical for Pin1 binding, and mutation of S118 to alanine prevents this association. Importantly, Pin1 isomerizes the serine118-proline119 bond from a cis to trans isomer, with a concomitant increase in AF1 transcriptional activity. Pin1 overexpression promotes ligand-independent and tamoxifeninducible activity of ER␣ and growth of tamoxifen-resistant breast cancer cells. Pin1 expression correlates with proliferation in ER␣-positive rat mammary tumors. These results establish phosphorylation-coupled proline isomerization as a mechanism modulating AF1 functional activity and provide insight into the role of a conformational switch in the functional regulation of the intrinsically disordered transactivation domain of ER␣.
strogen receptor alpha (ER␣), a member of the nuclear receptor superfamily of transcription factors, mediates the actions of estrogen in normal physiology and disease (17) . ER␣ is expressed in the normal mammary gland and in 70% of human breast cancers and is a key driver of breast cell proliferation (16, 26, 83) . Directed overexpression of ER␣ in the mammary gland is sufficient to induce hyperplasia, and blockade of ER␣ activity by hormonal therapies (aromatase inhibitors, tamoxifen, and fulvestrant) reduces recurrence and improves clinical outcomes of ER␣-positive breast cancer patients (19, 22) . Two activation functions mediate the transcriptional activity of ER␣, a C-terminal liganddependent AF2 and an N-terminal ligand-independent AF1 (89) . Regulation of ER␣ activity via the C-terminal AF2 has been wellcharacterized through biochemical and crystallographic studies and forms the basis for our understanding of hormonal therapy for breast cancer (10, 34, 84) . In the canonical activation pathway, ligand binding initiates C-terminal structural rearrangements that facilitate downstream events, including dimerization, DNA binding, and coregulator interactions, ultimately engaging the basal transcriptional machinery to regulate gene expression. However, ER␣ can also be activated by growth factors and kinases, which phosphorylate the receptor N terminus and other domains to regulate transcription in the absence of direct ligand engagement (for reviews, see references 27, 47, 75, 94, and 95) . In contrast to the C-terminal AF2 domain, biochemical and structural mechanisms that control N-terminal AF1 remain poorly understood (48, 91) .
Multiple challenges have hindered molecular dissection of AF1 regulation. First, AF1 resides in the receptor N terminus, which is an intrinsically disordered region and for which limited structural data are available (91) . Second, although the importance of phosphorylation in the regulation of this domain has been established, it is complicated by multiple sites of phosphorylation (3, 47) . Focus has been drawn to serine 118 (S118), since a single point mutation to alanine impairs both ligand-dependent and ligandindependent ER␣ activity (15, 20a, 42, 90) . Third, phosphorylation of S118 is induced by hormonal and nonhormonal activators such as estrogens and growth factors (2, 11, 42, 49) , kinases such as mitogen-activated protein kinase (MAPK), cyclindependent kinase 7 (cdk7), and glycogen synthase kinase 3␤ (GSK3␤) (2, 11, 14, 51, 65) , as well as the ER␣ inhibitor tamoxifen (33, 51, 80) . S118 phosphorylation has also been shown to recruit both a transcription coactivator (p68 RNA helicase and splicing factor SF3a p120) and the corepressor stromelysin 1 plateletderived growth factor-responsive element-binding protein (SPBP) (25, 31, 62, 92) . Finally, S118 phosphorylation has been implicated in both increased and decreased ER␣ protein stability (7, 12, 36, 61, 90) . Taken together, these observations point to a complex role of phosphorylation, and in particular for S118, in the regulation of AF1 that remains unresolved.
The N-terminal phosphorylation sites in ER␣ and several nuclear receptors consist of a conserved serine/threonine-proline (S/ T-P) motif, which is a recognition site for proline-directed kinases (75) . When phosphorylated, the phospho-S/T-P (pS/T-P) site also becomes a potential substrate for the peptidyl prolyl cis/trans isomerase Pin1. Pin1 is a unique phosphorylation-dependent prolyl isomerase composed of an N-terminal WW domain, involved in protein interaction, and a catalytic C-terminal prolyl isomerase (PPIase) domain. The WW domain preferentially binds to the pS/T-P motif, and the PPIase domain catalyzes cis-trans isomerization of the prolyl bond to regulate signaling (53-56, 73, 97, 100) . Such Pin1-catalyzed conformational regulation after phosphorylation often functions as a molecular timer, regulating many key proteins in diverse cellular processes (53, 56) . Importantly, Pin1 is overexpressed and correlates with poor patient outcome in many cancers, including breast cancer (88, 99) . This raises the possibility that Pin1-mediated isomerization of phosphorylated ER␣ regulates N-terminal functions in breast cancer cells.
Here, we establish that ER␣ AF1 activity is regulated by S118 phosphorylation-dependent recruitment of Pin1. Pin1 increases AF1-dependent transcription through a PPIase-dependent mechanism. We show that Pin1 binds directly to pS118 ER␣ and isomerizes ER␣ AF1 pS118-P119 from cis to trans. Pin1 imparts increased proliferation potential to breast cancer cells. In vivo, Pin1 expression is strongly associated with proliferation of ER␣-positive mammary cancers. These data suggest that like AF2, AF1 function can be regulated through conformational change, and they identify prolyl isomerization as a new mode of ER␣ regulation.
MATERIALS AND METHODS
Expression plasmids. Gal4-DNA binding domain (Gal4-DBD) constructs were gifts from Zafar Nawaz (University of Miami) and have been described elsewhere (13) . ER␣ expression vectors (wild type, hemagglutinin [HA] tagged, Sl18A, and L540Q) were constructed in an LHL-CA backbone (90) . The ER␣ L540Q mutant was a gift from Benita Katzenellenbogen (University of Illinois-Urbana-Champaign) (37) . Reporter genes consisting of the minimal estrogen response element and a thymidine kinase promoter driving the luciferase gene (ERE-tk-Luc) were previously described (93) , and a Gal4 binding luciferase reporter (pFR-Luc) was obtained from Agilent Technologies, CA. The construct RasV12G was a gift from Jing Zhang (University of Wisconsin-Madison) (102) . FlagPin1 was made as described previously (52) . Flag-Pin1 mutants K63A and W34A were made using the QuikChange mutagenesis kit (Stratagene, Agilent Technologies, CA). Green fluorescent protein (GFP)-carrying plasmids were constructed as reported elsewhere (86) . Flag-FKBP51 was provided by Edwin Sanchez (Medical College of Ohio). Constructs of ER␣ with C-terminally tagged Renilla luciferase (ER␣-RLUC) and yellow fluorescent protein (ER␣-YFP) were a gift from Wei Xu (70) .
Cell culture and treatments. MCF-7, MCF-7 cells expressing GFP or GFP-Pin1, HEK293T cells, a stable HEK293 cell line expressing HA-ER␣ or HA-S118A ER␣ (90) , and MDA-MB-231 cells were maintained under standard culture conditions as described in reference 24. Stable MCF-7 cells expressing GFP-tagged Pin1 or GFP vector were generated by viral infection and selection with 2 g/ml puromycin. Multiple independent stable pools were selected, and protein expression was confirmed by Western blot analysis with Pin1 antibody (57) and GFP-specific antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). MCF-7-5C, a tamoxifenresistant cell line (39) , was maintained in phenol red-free RPMI (Invitrogen, CA) supplemented with 10% dextran-charcoal-stripped fetal bovine serum, L-glutamine, nonessential amino acids (NEAA), 100 units/ml penicillin, 100 g/ml streptomycin (Invitrogen, CA), and 10 g/ml of insulin from bovine pancreas (Sigma, St. Louis, MO). In experiments involving treatment with ethanol (EtOH), 17␤-estradiol (E2), epidermal growth factor (EGF), or 4-hydroxytamoxifen (OHT), cells were placed in estrogen-deprived medium consisting of phenol red-free Dulbecco's modified Eagle's medium (DMEM; Cellgro, Mediatech Inc., VA) with 10% dextran-charcoal-stripped fetal bovine serum for 3 days prior to the addition of hormone or vehicle. For EGF treatments, the medium was changed to phenol red-free DMEM or Opti-MEM (Invitrogen, CA) overnight prior to treatment. The treatments were carried out for the times indicated below in the figure legends.
Animals. Fifty-day-old Sprague-Dawley rats (Charles River Laboratory) were ovariectomized, implanted with silastic pellets producing physiological levels of E2 (2.5 mg/1-cm silastic pellet), and treated with 50 mg/kg of body weight 7,12-dimethylbenz[␣]anthracene (DMBA) intragastrically to induce mammary tumors as previously described (41) . Tumor-bearing rats were euthanized 2 h after intraperitoneal injection with 5-bromo-2-deoxyuridine (BrdU; 70 mg/kg; Sigma, St. Louis, MO). All animal handling procedures were approved by the Michigan State University (MSU) Committee on Animal Use and Care.
Immunohistochemistry and immunocytochemistry. For mammary tumor sections, labeling with mouse monoclonal anti-Pin1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or mouse monoclonal antiBrdU antibody (anti-BrdU detection kit; Amersham, Little Chalfont, Buckinghamshire, United Kingdom) was performed as previously described (40) . Images were captured with a Nikon inverted epifluorescence microscope (Mager Scientific) and analyzed with MetaMorph software (Molecular Devices Corporation, Sunnyvale, CA). Captured images were used to quantitate Pin1 ϩ or BrdU ϩ cells detected by immunofluorescent labeling, and the number of positive cells was expressed as the percentage of total tumor cells counted.
Immunocytochemistry in MCF-7 cells was performed as previously described (29) . Primary antibodies included anti-ER␣ (HC-20; Santa Cruz Biotechnology, CA) and anti-Pin1 (57) . Secondary antibodies included anti-mouse IgG-fluorescein isothiocyanate (Sigma, St. Louis, MO) or anti-rabbit IgG-rhodamine red (Molecular Probes, Invitrogen, CA). Images were acquired using an Olympus fluorescence microscope with 20ϫ magnification and exported to Adobe Photoshop.
Reporter gene assays. Assays were performed as previously described (90) in MDA-MB-231 cells or HEK293T cells as indicated in the figure legends. Expression constructs included LHL-CA-ER␣ or L540Q mutant, Gal4 fusion constructs consisting of Gal4-DBD fused to AF1, AF2, or Gal4-DBD alone, Flag-or GFP-tagged Pin1 and mutants, and Flag-FKBP51. Reporter genes consisted of ERE-tk-Luc or pFR-Luc, as appropriate. Equal amounts of DNA were transfected, and transfection efficiency was controlled by cotransfection with cytomegalovirus ␤-galactosidase (CMV-␤-Gal). Luciferase (Luciferase assay system; Promega, Madison, WI) and ␤-galactosidase (Glacto-Light Plus; Tropix Inc., MA) assays were performed as per the manufacturers' protocols. Treatments conditions with EtOH, E2, EGF, or OHT are described in the figure legends. Treatment with EGF was performed in reduced serum Opti-MEM (Invitrogen, CA).
Coimmunoprecipitation and glutathione S-transferase (GST) pulldown. Coimmunoprecipitation was performed in MCF-7 cells starved in serum-free DMEM with 1% bovine serum albumin (BSA; Sigma, St. Louis, MO) for 3 days. Cells were then stimulated with 0.1% EtOH or 10 nM E2 for 30 min with 1 M okadaic acid (Roche, NJ) added during the final 10 min. Cells were lysed in 25 mM HEPES (pH 7.0), 40 mM NaCl, 0.2% NP-40, 15% glycerol, 1 mM Juglone, with protease and phosphatase inhibitors. Pin1 (Santa Cruz Biotechnology, Santa Cruz, CA) or normal mouse IgG antibody-protein A/G 1:1 agarose beads (Invitrogen, CA) complexes were allowed to form for 45 min, and cell lysates were incubated with the antibody-bead complexes for 2 h. The antibody-bound complex was washed 4 times with lysis buffer, and proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting for Pin1 (Santa Cruz Biotechnology) or ER␣ (Stressgen; Enzo Life Sciences, NJ) using appropriate antibodies. Input lanes contained 1% whole-cell extracts prior to immunoprecipitation.
All GST-tagged proteins were expressed and purified as previously reported (100, 103) . GST pulldown assays were performed as described previously (103) with purified GST, GST-Pin1, GST-WW, GST-PPIase, and GST-Pin1 W34A and whole-cell extracts of MCF-7 cells or HEK293 cells with stable or transient expression of HA-ER and HA-ER␣ S118A (90) treated with E2, EGF, EtOH, OHT, or alkaline phosphatase (PPase) as indicated in the figure legends. For treatment with EGF, medium was changed to phenol red/serum-free DMEM for overnight incubation.
In vitro phosphorylation of the ER␣ 39 -160 fragment. The purified ER␣ 39 -160 fragment with and without uniform (U) 15 N labeling was produced at the Center for Eukaryotic Structural Genomics (CESG) at UWMadison by using an Escherichia coli cell-based platform (60) . Commercial MAPK containing an N-terminal GST tag (Millipore, MA) was used to phosphorylate the ER␣ 39 -160 fragment. The kinase reaction was carried out as described previously (51) in 25 mM Tris (pH 7.5), 25 mM MgCl 2 , 10 mM dithiothreitol (kinase buffer), 10 M ATP, and ER␣ 39 -160 in the presence and absence of 5 g of kinase. The reaction mixture was incubated at 30°C for 4 h. Phosphorylation of ER␣ 39 -160 at S118 was confirmed by Western blotting using pS118 ER␣-specific antibody (Cell Signaling Technology, MA). Site-specific phosphorylation at S118 was further confirmed by Western blotting with antibody specific for phosphoserines 104/106 in ER␣ (Cell Signaling Technology, MA). Equivalent loading was confirmed by reprobing with ER␣-specific antibody (H184; Santa Cruz Biotechnology, Santa Cruz, CA). The phosphorylated fragment was further purified by incubating the reaction mixture with glutathione (GSH)-agarose (Sigma, St. Louis, MO) in the presence of apigenin (Sigma) to block MAPK activity.
In vitro dephosphorylation assay. Purified, in vitro-phosphorylated ER␣ 39 -160 fragment (120 ng) was incubated with 100 ng of purified PP2A holoenzyme (a gift from Yongna Xing, UW-Madison) and 2 g of purified GST (control) or GST-Pin1 in kinase buffer with 50 mM Tris (pH 7.5), 50 mM NaCl, 50 M MnCl 2 in the presence or absence of 10 M Juglone (Pin1 inhibitor; Sigma) at 30°C. The reaction was terminated with addition of SDS sample buffer at the indicated times, and phosphorylation was assessed by Western blotting using pS118 ER␣-specific antibody (Cell Signaling Technology, MA). Equivalent loading was confirmed by reprobing with ER␣-specific antibody (H184; Santa Cruz Biotechnology).
NMR spectroscopy. Nuclear magnetic resonance (NMR) samples contained 0.5 mM [U- 15 39 -160 were acquired in the absence of Pin1; then, the changes in the amide chemical shifts were monitored as Pin1 was added to a maximum of 10:1 (Pin1:ER␣ 39 -160 ). NMR data were acquired on a Varian Inova 600-MHz ( 1 H frequency) spectrometer equipped with a cryogenic probe; the NMR probe temperature was maintained at 25°C. 1 H-15 N HSQC NMR spectra (43) were acquired with a total spectral acquisition time of 1.5 h for each sample. All NMR spectra were processed with nmrPipe (18) and analyzed using XEASY (4).
Far-Western blotting assay. The far-Western blotting method was previously described (23) . Briefly, phosphorylated and unphosphorylated ER␣ 39 -160 fragments were separated by gradient SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, MA). Membranes were incubated with GST, GST Pin1, or GST Pin1 S16E proteins for 4 h at 4°C with gentle agitation. Following a rinse with wash buffer 1 (0.2% Triton X-100 in phosphate-buffered saline [PBS]) and wash buffer 2 (0.2% Triton X-100 and 100 mM KCl in PBS), Western blot analysis was performed on the membrane with anti-GST antibody (Santa Cruz Biotechnology).
BRET assay. Bioluminescence resonance energy transfer (BRET) assays were conducted as described in reference 70. Briefly, HEK293T cells were placed in phenol red-free DMEM supplemented with 10% dextrancharcoal-stripped fetal bovine serum (estrogen deprived). The cells were then first transfected with either empty vector or Flag-Pin1. After 24 h, cells were cotransfected with plasmids encoding ER␣ fusion proteins with a C-terminal Renilla luciferase (ER␣-RLUC) or ER␣-YFP. These fusion proteins have been well characterized for their functional activities (70) .
Control wells were transfected with ER␣-RLUC and an empty vector or pCMX-YFP for background and bystander calculations. Following treatment of cells with EtOH for 1 h, coelententerzine-h (Promega, WI) was added to a final concentration of 5 M per well. Emission levels at 450 and 540 nm were measured using a Synergy plate reader (BioTek Instruments, VT). BRET ratios were calculated, including correction for signals from random collision, i.e., bystander BRET, as described in reference 70.
Growth assays. Anchorage-independent soft agar colony formation assays using MCF-7 cells transfected with either Pin1 small interfering RNA (siRNA) or scrambled (scr) siRNA (Qiagen, Valencia, CA) were conducted using 0.8% SeaPlaque agarose (Cambrex) as previously described (71) . Colonies were visualized by staining with 0.005% crystal violet solution, and numbers were determined by manual counting. Tamoxifen-resistant breast cancer MCF-7-5C cells (39) were placed in phenol red-free DMEM supplemented with 10% dextran-charcoalstripped fetal bovine serum (estrogen deprived) and were transfected with Pin1 siRNA or scrambled siRNA (Qiagen, CA) followed by 1 M OHT treatment for 0, 24, or 48 h. At the indicated times, MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma, St. Louis, MO] was added at a final concentration of 0.5 mg/ml, and cell growth was measured using the manufacturer's protocol. MCF-7 cells overexpressing GFP or GFP-Pin1 were treated with 1 M OHT for 0, 24, 48, or 72 h, and growth was assessed by crystal violet staining in which cells were stained with 0.4% crystal violet solution (Sigma, MO) for 10 min, washed with water, and lysed in 50% methanol for 10 min with gently shaking. The optical density of the lysis solution was measured at a 540-nm wavelength.
Statistical analysis. Student's t test was used to assess significant differences between control and treated samples using Microcal Origin software (OriginLab Corporation, MA). Correlation of Pin1 and BrdU uptake was calculated using the Pearson correlation coefficient function in Microsoft Excel. P values of less than 0.05 were considered significant and are indicated by asterisks in the figures.
RESULTS
Pin1 is necessary for optimal growth of ER␣-positive breast cancer cells. Hormone-dependent ER␣ ϩ mammary tumors were induced by treatment of ovariectomized rats with the carcinogen 7,12-dimethylbenz[␣]anthracene and exogenous 17␤-estradiol (E2) as described in reference 41. To determine whether Pin1 plays a role in ER␣-dependent tumor growth in vivo, Pin1 expression and proliferation were evaluated in individual tumors. In all tumors examined (n ϭ 15), 28 to 88% (mean, 57%; median, 52%) of tumor cells expressed nuclear Pin1 (Fig. 1A, yellow arrow) . The proliferation rate, as assessed by BrdU incorporation (Fig. 1B) , was significantly correlated (P Ͻ 0.005) with nuclear Pin1 expression (Fig. 1C) , providing initial evidence that Pin1 is related to growth of ER␣ ϩ tumors. Next, we asked if ER␣ ϩ breast cancer cells are dependent on Pin1 for growth by using anchorageindependent colony formation assays and siRNA knockdown techniques. MCF-7 cells transfected with scr siRNA showed the expected increase in colony number upon treatment with E2 (Fig.  1D) . However, knockdown of Pin1 markedly decreased (ϳ3.5-fold) the number of colonies in both vehicle (EtOH)-treated and E2-treated cells. Immunofluorescence microscopy showed that Pin1 was also nuclear in MCF-7 cells and colocalized with ER␣ (Fig. 1E) . Thus, Pin1 is functionally significant in growth control of ER␣-dependent breast tumors and MCF-7 breast cancer cells, potentially through regulation of ER␣ activity.
ER␣ AF1 transcriptional function is regulated by Pin1 binding and catalytic activities. Possible regulation of ER␣ transactivation by Pin1 was previously suggested by the results of Yi et al., who showed that estrogen-dependent induction of TFF1, a direct target gene of ER␣, was diminished by Pin1 knockdown (101) . Expanding on this observation, we tested whether Pin1 directly regulated ER␣ transcriptional function. Reporter gene assays were carried out with transfected wild-type (WT) ER␣ and Pin1 in MDA-MB-231 breast cancer cells by using a defined reporter consisting of a minimal estrogen response element (ERE) and a thymidine kinase promoter driving luciferase gene (ERE-tk-Luc). In agreement with previous findings (101), Pin1 increased ER␣-dependent reporter gene activity ( Fig. 2A ). Pin1's ability to enhance ER␣-dependent transcription was further confirmed in MCF-7 MVLN cells with a stably integrated ERE reporter (69) (see Fig. S1A in the supplemental material). However, we noticed that Pin1 significantly increased ER␣ activity in both the absence of E2 (EtOH control) and at low concentrations of E2 (Fig. 2A) . The ability of Pin1 to regulate ER␣ transcription, under E2-depleted conditions, prompted us to independently assess Pin1 regulation of isolated ER␣ transactivation domains.
To begin to define the mechanism by which Pin1 regulates ER␣ transcriptional activity, we employed an ER␣ mutant (L540Q) that disrupts the AF2 function by interfering with coactivator interactions (1, 37) . Interestingly, Pin1 increased the transcriptional activity of the L540Q mutant in both the presence and absence of E2 (Fig. 2B) . Furthermore, examination of transcriptional activation by isolated AF1 or AF2 domains tethered to a Gal4-DBD revealed that Pin1 failed to stimulate AF2 function (Fig. 2C ) and instead increased AF1 activity by ϳ5-fold over control cells. A similar increase in Pin1-induced AF1 activity was detected when cells were treated with EGF (Fig. 2D ) or when transfected with a constitutively active Ras mutant (RasV12G) (see Fig. S1B in the supplemental material), both of which are known to selectively act on AF1 through phosphorylation by activating the MAPK pathway (11) . These results imply that Pin1 can enhance both estrogen-and growth factor-inducible AF1 activities. The W34A mutation in the WW domain and K63A mutation in the PPIase domain abolish binding and the isomerase activity of Pin1, respectively (77) . To test if the catalytic and binding activities of Pin1 are required for enhancement of AF1 function, we overexpressed Flag-Pin1, Flag-Pin1 K63A, and Flag-Pin1 W34A in HEK293T cells and measured the transcriptional potential of AF1 Gal4-DBD. Neither mutant significantly increased AF1 activity (Fig.  2E) . Similarly, Pin1 lacking the catalytic PPIase domain (GFP-WW) was also unable to enhance AF1 activity (see Fig. S1C ). The increase in AF1 activity appeared to be Pin1 specific, as overexpression of another prolyl cis/trans isomerase FK506 binding im- munophilin (FKBP51) did not enhance AF1 transactivation (Fig.  2E) . Taken together, these data indicate that Pin1 stimulates ER␣ transcriptional activity via the AF1 domain in a manner that requires both the catalytic activity and substrate binding functions of Pin1.
Phosphorylation of ER␣ at S118 is necessary for Pin1 association with ER␣. We next assessed the possibility that ER␣ might be a direct target of Pin1. ER␣ contains four putative S-P motifs (S104P, S106P, S118P, and S294P) (Fig. 3A) . Phosphorylation of any of these serine residues could create a Pin1 binding site. Coimmunoprecipitation experiments performed with extracts from MCF-7 cells that were maintained in serum-free medium showed that endogenous Pin1 and ER␣ are in a protein complex (Fig. 3B) . This interaction was detectable upon E2 treatment, consistent with E2-stimulated phosphorylation of AF1 (14) . Pin1 interaction with ER␣ was further confirmed by a GST pulldown assay using ϳ19 kDa) , and Flag-FKBP51 (molecular mass, ϳ52 kDa), assessed by Western blotting using a Flag-specific antibody. Data in all panels are represented as means Ϯ SEM for at least three independent experiments. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; ‫,ءءء‬ P Ͻ 0.001, comparing EtOH-(A and B), E2-(C and E), or EGF-treated (D) Pin1-and vector-transfected samples. #, P Ͻ 0.05, comparing Pin1-and vector-transfected E2-treated samples (A and B); a, P Ͻ 0.05 comparing EtOH-and E2-treated vector-only transfected cells; ns, not significant (P Ͼ 0.05) for vector-transfected versus Pin1 mutant/FKBP51-transfected samples (E).
GST or GST-Pin1 and cell extracts from estrogen-depleted MCF-7 cells supplemented with 10% dextran-charcoal-stripped fetal bovine serum (Fig. 3C) . While E2 increased Pin1 recruitment to ER␣, Pin1 was also detected in the absence of E2; however, this interaction was abolished by PPase treatment of the extracts (Fig.  3C) , indicating the requirement for phosphorylation. We thus asked whether growth factors, which are present in estrogendepleted medium, could account for Pin1-ER␣ interactions under these conditions. MCF-7 cells were thus maintained in serum-free medium and treated with EGF. GST pulldown experiments showed that in the absence of serum, Pin1 did not associate with ER␣ in cell extracts, but EGF stimulation was sufficient to promote Pin1 recruitment to the ER␣ complex (Fig. 3D) . Accordingly, Pin1 substrate binding WW domain (Fig. 3E) and, specifically, tryptophan (W34) within this domain (77) , were required for ER␣ association (Fig. 3F) . Both E2 and EGF induce phosphorylation of ER␣ of S118, albeit via different kinase pathways (14, 42) . Mutation of S118 to alanine abolished the Pin1-ER␣ association (Fig. 3G) . To assess the direct interaction between pS118 ER␣ AF1 and Pin1, we generated a purified AF1 fragment consisting of amino acids 39 to 160 (ER␣ 39 -160 ) (see Fig. S2 in the supplemental material) that could be phosphorylated in vitro with MAPK (Fig. 4A) . By far-Western analysis, blots of unphosphorylated ER␣ 39 -160 or pS118-ER␣ 39 -160 were hybridized with purified recombinant GST-Pin1, GST-Pin1-S16E (binding-deficient mutant), or GST as a control. Probing blots with GST antibody showed that GST-Pin1, but not GST-Pin1-S16E or GST alone, interacted with pS118-ER␣ 39 -160 and not with ER␣ 39 -160 (Fig.  3H) . Thus, Pin1 can directly recognize the pS118-P119 moiety in the ER␣ AF1 domain. Thus, inducible phosphorylation of ER␣ at S118 is necessary to bring Pin1 into the ER␣ complex, where Pin1 can bind directly to pS118-ER␣ through the substrate binding WW domain.
Pin1 induces cis-trans isomerization of the pS118-P119 bond of ER␣ AF1. In contrast to the well-structured DBD and C-terminal domain (CTD), the N-terminal domain (NTD) of ER␣ is disordered, and little information exists regarding the impact of pS118 or phosphorylation in general on the ER␣ NTD (48) . To begin to probe potential conformational regulation of ER␣ AF1 by Pin1, we first assessed the impact of S118 phosphorylation. A uniformly 15 N-labeled ER␣ 39 -160 AF1 fragment was purified (Fig. 4A, upper blot) and in vitro phosphorylated using MAPK. These conditions resulted in selective phosphorylation of S118 but not S104 or S106 (Fig. 4A, lower blot) , consistent with a previous report (51 39 -160 ) (blue) showed that although both spectra exhibited limited peak dispersion in the 1 H dimension and remained disordered, phosphorylation led to significant changes in the positions of many peptide backbone cross peaks (Fig. 4B) . These changes suggested that phosphorylation of S118 is associated with local as well as more extensive conformational changes within the AF1 domain. GST pulldown assays were performed with extracts from stable HEK293 cells expressing HA-tagged wild-type ER␣ treated with 10 nM E2 for 30 min and incubated with GST, GST-Pin1, GST-WW (Pin1 mutant lacking the PPIase domain), or GST-PPIase (Pin1 mutant lacking the WW domain). Shown is a representative Western blot with an anti-HA antibody for ER␣ (HA-ER␣) and an anti-GST antibody for GST. Results from Western blot analysis with anti-HA antibody for ER␣ in cell extracts prior to pull down is shown in the input panel. (F) GST pulldown assays were performed as described for panel E using GST, GST-Pin1, and GST-Pin1 W34A (substrate binding Pin1 point mutant). Shown is a representative Western blot analysis for ER␣ (HA) and GST. The input panel represents Western blot analysis results for ER␣ in cell extracts prior to pulldown. (G) A GST pulldown assay was performed using cell extracts from HEK293 cells stably expressing WT or S118 phosphorylation site mutant (S118A) ER␣ that had been stimulated with 10 nM E2 as for panel C. Shown is a representative Western blot analysis for ER␣. (H) Pin1 binds directly to the phosphorylated ER␣ fragment. Far-Western analysis was performed as described in Materials and Methods. A purified fragment of ER␣ from amino acids 39 to 160 (ER␣ 39 -160 ) was purified, and a fraction was phosphorylated in vitro with purified MAPK as described in the text. Blots of unphosphorylated (ER␣ 39 -160 ) and phosphorylated (pS118-ER␣ 39 -160 ) forms were transferred to a PVDF membrane following gel electrophoresis. The membrane was incubated with GST, GST-Pin1, or GST-Pin1 S16E (substrate binding Pin1 mutant) and probed for GST using anti-GST. Reprobing the blot for ER␣ showed equivalent loading. S/T-P motifs in a peptide bond, including S118, can exist in two conformations, cis or trans (Fig. 4C) , but phosphorylation hinders the spontaneous isomerization of the prolyl bond by trapping the isomer predominantly in the cis conformation (81, 96, 100) . As Pin1 can bind directly to the pS118-ER␣ 39 -160 fragment (Fig. 3H) , it is plausible that Pin1 may isomerize the pS118-P119 bond of ER␣ 39 -160 AF1. To test this, we employed a dephosphorylation assay using PP2A, which preferentially dephosphorylates trans-Ser/Thr-Pro motifs and has been used as a tool to efficiently differentiate the isomeric status of Pin1 substrates (104) (Fig. 4C) . Phosphorylated ER␣ 39 -160 fragment was coincubated with GST or GST-Pin1 in the presence of purified PP2A for various lengths of time, and the remaining amount of phosphorylated ER␣ was determined by Western blot analysis using pS118-ER␣ antibody. As shown in Fig. 4D , dephosphorylation of pS118-ER␣ 39 -160 occurred more rapidly in the presence of Pin1 than control GST. In addition, this dephosphorylation was inhibited by coincubation with Juglone, a Pin1 inhibitor (35) that has no effect on PP2A activity (28) , indicating that Pin1 can directly accelerate isomerization of the pS118-P119 peptide bond of ER␣ from cis to trans. Indeed, NMR analysis following addition of a 10-fold molar excess of Pin1 led to small changes in the HSQC spectra of phosphorylated pER␣ 39 -160 (Fig. 5A ), but not of unphosphorylated ER␣ 39 -160 (Fig. 5B) , indicating a local phosphorylationdependent conformational change.
Since there was no structural information regarding how Pin1 might recognize pS118-P119 bond, we generated a computer model of this complex (see Fig. S3A in the supplemental material). The Pin1 structure was derived by removal of the Ala-Pro dipeptide, sulfate ion, and polyethylene glycol 400 molecules from the crystal structure by Ranganathan et al. (73) and modeled with the 4-amino-acid peptide of ER␣ (L 117 pS 118 P 119 F 120 ; shown in green in the catalytic site of Pin1). Shown also are the amino acid side chains, such as K63, R68, and R69, of the PPIase domain of Pin1 (pink) surrounding the pS118-P119 ER␣ peptide. These interactions could orchestrate the catalysis of the pS118-P119 peptide bond rotation from cis (, 0°) to trans (, 180°) (73) . Indeed, mutation of K63 to alanine abolished Pin1-mediated effects on AF1 activity (Fig. 2E) . This model supports the notion that via a "tag-and-twist" mechanism proposed for Pin1 (55), a kinase tags (phosphorylates) the pS118-P119 motif, and Pin1 subsequently binds and twists (isomerizes) the pS118-P119 prolyl bond to introduce a kink or new conformation that could alter ER␣ AF1 function. The local conformational changes induced by proline isomerization in flexible domains have been shown to propagate to other regions of a protein, allosterically controlling their form 39 -160 were phosphorylated in vitro with purified MAPK as described in Materials and Methods. Phosphorylation of ER␣ was assessed by Western blot analysis using site-specific antibodies against phosphorylated S118 (pS118-ER␣) and phosphorylated S104/106 (pS104/106-ER␣). Western blot results for total ER␣ are shown in the bottom panel. (B) NMR analysis of unphosphorylated ER␣ 39 -160 and phosphorylated ER␣ 39 -160 (pER␣ 39 -160 ) was performed as described in Materials and Methods. Shown is an overlay of the 2D 1 H-15 N HSQC spectra (600 MHz 1 H), recorded at 25°C, of ER␣ 39 -160 (red) and pER␣ 39 -160 (blue). (C) Models representing cis and trans conformations of the pSer118-Pro119 bond. A schematic of the ER␣ NTD from amino acids 39 to 160 is shown on top and represents purified ER␣ 39 -160 as a disordered peptide. The stick model shows the phosphorylated pSer118-Pro119 bond in cis and trans conformations and potential catalysis by Pin1. PP2A selectively dephosphorylates the trans isomer and was used as a biochemical tool to assess cis and trans isomers of the pSer118-Pro119 bond of ER␣. (D) An in vitro dephosphorylation assay was performed using S118 phosphorylated ER␣ 39 -160 and purified PP2A as described in Materials and Methods. Phosphorylated ER␣ 39 -160 , in the presence of GST, GST-Pin1, or GST-Pin1 plus Juglone (Pin1 inhibitor), was treated with 100 ng PP2A for the indicated length of time. Western blot analysis was then performed for pS118-ER␣ and ER␣. Shown is a representative Western blot of three independent experiments. and function (78, 79) . To assess the possibility that Pin1-directed changes in the N terminus can be propagated to other ER␣ functional domains, a BRET assay was used that measured the energy transfer from activated Renilla luciferase to a YFP fused to the C termini of two separate ER␣ constructs (ER␣-RLUC and ER␣-YFP) under estrogen-deprived conditions (70) (Fig. 5C, upper  panel) . This assay has been used in previous studies to assess conformational changes associated with receptor dimerization (20, 45, 70) that can be mediated through the DNA and C-terminal ligand binding domains (10, 46, 82) . Increased energy transfer (ϳ8-fold compared to vector) occurred upon overexpression of Pin1 (Fig. 5C, lower panel) in the absence of E2 and was abolished by S118 alanine substitution (see Fig. S3B ), indicating that Pin1-induced changes, which originate in the N terminus of ER␣, can induce subsequent modifications that increase the proximity of the C-terminal domains of two receptor monomers. These data demonstrate that phosphorylation-coupled events initiated in the AF1 region can be transmitted to other domains and promote downstream events, potentially receptor dimerization, that could increase transcriptional activation in the absence of ligand.
Pin1 promotes tamoxifen resistance in ER␣-positive breast cancer cells. Acquisition of tamoxifen resistance in breast cancer can result from increased AF1 function (5, 63, 74) . Since Pin1 increases AF1 transcriptional activity and was necessary for ER␣ ϩ breast cancer cell growth, Pin1 could be functionally coupled to tamoxifen resistance in ER␣-dependent breast cancer cells. To test this possibility, we first evaluated whether Pin1 increased ER␣ activity in the presence of tamoxifen. Upon OHT (a potent tamoxifen metabolite) treatment, Pin1 increased the transcriptional activity of ER␣ by ϳ3.5-fold over vector controls (Fig. 6A) . Consistently, Pin1 also enhanced transcription in the absence of ligand (EtOH). The GST pulldown assay also indicated that Pin1 forms a complex with ER␣ in the presence of OHT, which is dependent on an intact S118 residue (Fig. 6B ). These data indicate that similar to E2 and EGF, tamoxifen also induces recruitment of Pin1 to ER␣ transcriptional complexes in an S118-dependent (i.e., AF1-dependent) manner. Next, we asked if tamoxifen-dependent growth was susceptible to regulation by Pin1. Knockdown of Pin1 in MCF-7-5C cells, a tamoxifenresistant derivative of MCF-7 cells (39), caused both a basal decrease (P ϭ 0.053) and a significant inhibition in tamoxifeninduced growth during 24 and 48 h of OHT treatment (Fig. 6C) and, reciprocally, stable overexpression of Pin1 in the MCF-7 breast cancer cell line resulted in increased growth in the pres- ence of OHT compared to controls (Fig. 6D) . Thus, tamoxifen can promote growth of breast cancer cells, at least in part by inducing recruitment of Pin1 to pS118-ER␣, which in turn enhances AF1 activity.
DISCUSSION
ER␣'s role in breast cancer biology is well-established. It is the single most important predictive biomarker for response to therapy, and it is the molecular target for the most commonly prescribed breast cancer therapeutics. ER␣ controls growth of breast cancer cells through the regulation of gene expression, and antagonization of ER␣ transcriptional function by interfering with ligand-dependent transcriptional activity (tamoxifen or aromatase inhibitors) or degrading ER␣ protein forms the basis of current hormonal therapies. The regulatory events involved in ligand-dependent transcriptional activation of ER␣ via the AF2 domain have been extensively investigated (6, 38, 64, 68) . While it was recognized early on that ER␣ transcriptional function involves both AF1 and AF2 (89) , an understanding of the regulatory mechanisms governing AF1 have proven elusive. To fully control ER␣ activity in breast cancer, however, surely requires an understanding of the control of both the AF1 and AF2 domains. This study establishes a previously unrecognized mechanism by which phosphorylation controls AF1 activity. Our results show that phosphorylation of ER␣ at S118 induces chemical shifts that resonate throughout the AF1 domain and allows direct binding of Pin1 to ER␣. Pin1 causes isomerization of the pS118-P119 bond, leading to additional local changes in chemical structure. Coordinately, Pin1 promotes dimerization of ER␣ and enhances receptor transcriptional function independently of a stimulus via AF1. Importantly, the increased AF1 transcriptional function of ER␣ conferred by Pin1 depends on the isomerization function, which is necessary to accelerate the conversion of the ER␣ AF1 domain from the cis to trans isomer, thereby coupling conformational reorganization to enhanced AF1 function. This enzyme-driven increase in AF1 activity could account in part for hormoneindependent growth progression and tamoxifen resistance in breast cancer cells.
Our data indicate that Pin1 can act directly on ER␣ and modulate ER␣ activity. GST pulldown and far-Western analyses, as well as direct interaction of purified components, clearly indicate that Pin1 can form a complex with ER␣ that is dependent on pS118 in the absence of other factors. Reporter gene transcriptional assay results further support the conclusion that Pin1 catalytic activity acts specifically to control the AF1 but not the AF2 domain of ER␣. However, Pin1 is a ubiquitously expressed protein that has several binding partners (97) , and it cannot be excluded that the Pin1-mediated increase in ER␣ transactivation and growth of normal and tamoxifen-resistant breast cancer cells could be both direct and indirect (67, 97) . Both estrogen and tamoxifen cause S118 phosphorylation in the AF1 domain, yet they also induce differential recruitment of coactivator and corepressors, respectively, to the AF2 domain (10, 84) . The ER␣-interacting factors amplified in breast cancer 1 (AIB1) (101) and silencing mediator for retinoid or thyroid hormone receptors (SMRT) (85) also interact with Pin1 and could modulate ER␣ function. Yet, we observed that Pin1 was able to increase the transactivation potential of an ER␣ mutant (L540Q) which is compromised in coactivator interactions and does not bind AIB1 (1, 37) . Nevertheless, our studies indicate that phosphorylation of S118 is necessary and sufficient for the Pin1 interaction with both estrogen and tamoxifen stimulation. Besides Pin1, S118 phosphorylation at the AF1 domain has been shown to recruit p68 RNA helicase and splicing factor SF3a p120, which act as AF1 coactivators, and SPBP, which behaves as a corepressor (25, 31, 62, 92) . Although these pS118-dependent factors have not yet been determined as Pin1 substrates, it is tempting to speculate that the mechanism by which Pin1 enhances AF1 activity could be through direct actions on ER␣ and differential recruitment of these factors. Structural changes induced by Pin1 could create a stronger binding pocket for coactivator interaction, or such changes could alter the dynamics of the site inhibiting corepressor binding. Such Pin1-mediated changes in protein-protein interactions have been known to enhance transcription and protein stability of other proteins, including p53, p72, beta-catenin, and NF-B (59, 76, 77, 98) . Therefore, under different experimental conditions, and perhaps physiologic or pathological settings, distinct Pin-1-mediated mechanisms may predominate to control ER␣ activity.
One of the factors contributing to the general lack of understanding of ER␣ AF1 regulation is the lack of structural information of this domain. While the AF2 domain is located within the ligand binding domain and crystal structures exist for the CTD ligand-containing AF2 and DBD (82, 84) , structural information on the AF1 domain is lacking. The ER␣ N terminus, including the AF1 domain, is unstructured but regulated through phosphorylation signaling (47, 48) . Based on surface plasmon resonance and circular dichroism, Wärnmark et al. reported that the flexible ER␣ NTD is not resistant to structural changes and putatively can adopt an increase in order upon binding to the TATA box binding protein (TBP) (91). Gburcik et al. speculated that structural changes could be a mechanism controlling AF1 (32); however, the role of phosphorylation in the structural regulation of this region was unknown. To our knowledge, our NMR analyses of the N-terminal ER␣ 39-160 fragment in different configurations (unphosphorylated, S118 phosphorylated, and S118 phosphorylated plus Pin1) provide the first insight into structural modulation within this "unstructured" domain upon covalent modification. Our NMR study showed that S118 phosphorylation alone (in the absence of Pin1 action) caused significant changes in the positions of many peptide backbone cross peaks in ER␣ , suggesting that structural changes due to phosphorylation at a single site can propagate within the domain, leading to the global conformational changes of the otherwise-unstructured N terminus. This is not due to dimerization, since this domain cannot dimerize (46, 50, 87) . Addition of purified recombinant Pin1 induced a further change, but the magnitudes of chemical shifts in this case were relatively small, indicative of a specifically localized change. This change could result from cis-to-trans isomerization of the pS118-P119 bond of the ER␣ fragment by Pin1, as shown in our in vitro PP2A assay. Given our biochemical analysis results, we propose a model in which the unphosphorylated ER␣ N terminus exists in equilibrium between the cis and trans conformers. Upon S118 phosphorylation, the ER␣ N terminus is preferentially held in the cis conformation, which is associated with a large-scale structural change within this domain. Upon Pin1 action on pS118-P119, the AF1 domain is subsequently altered to the trans conformation, involving a further but relatively modest local structural change. Additional NMR studies employing both double-labeled ( 13 C and 15 N) and larger segments of ER␣ will be helpful in further defining phosphorylation-and Pin1-directed structural changes. This is a plausible approach, as such structural changes upon Ser/Thr phosphorylation have been reported for other intrinsically disordered proteins (21, 72) . Such studies, combined with additional analyses as demonstrated with our BRET results, will be useful in defining the role of N-terminal structural changes in modulating overall ER␣ structure and function.
The regulation of Pin1 at the N terminus may not be exclusive to ER␣ and may be conserved among other nuclear receptors. The N-terminal domains of several members of the nuclear steroid receptor family of transcription factors, such as PR, GR, AR, and ER␤, also contain putative Pin1 recognition motifs (75) . The N termini of these receptors are otherwise unrelated; thus, the conservation of the Pin1 recognition motif in combination with the established ligand-and growth factor-induced phosphorylation of these sites strongly suggests that the Pin1 recognition may be functionally conserved among nuclear receptors. Indeed, Fujimoto et al. previously showed that an N-terminal S84P mutant of peroxisome proliferator-activated receptor gamma (PPAR␥) is a substrate for Pin1 (30) . Similarly, Brondani et al. provided evidence that Pin1 interacted with the S77P motif of retinoid acid receptor alpha (RAR␣) (9) . In the case of PPAR␥, catalytic activity of Pin1 is dispensable for PPAR␥ regulation and negatively affects PPAR␥ transcriptional function, which is in contrast with our findings with ER␣. Unique to our study is the direct assessment of the structural changes and cis-trans isomerization of a nuclear receptor NTD by Pin1. Despite the conservation of the S/T-P site in the NTD, the NTD itself is the least-conserved region among nuclear receptors, which could lead to differential regulation of receptor function by Pin1. However, our current study along with these previous studies on other nuclear receptors point to a phosphorylation-dependent isomerization by Pin1 as a general regulatory mechanism for the N-terminal domain of several nuclear steroid receptors.
Regulation of ER␣ phosphorylation is strongly linked to breast cancer progression but a "phosphorylation paradox" exists, wherein ER␣ S118 phosphorylation is associated with enhanced differentiation and slower cancer cell growth and yet also accelerates growth in the presence of antiestrogens (66, 80) . Our data concur with several reports that phosphorylation at S118 is associated with increased growth in the presence of tamoxifen (8, 44, 51, 58) . The biochemical data suggest a further modification beyond phosphorylation (i.e., isomerization) that could influence the outcome. Although our analyses are limited to an ER␣ fragment due to the size limitations of NMR analysis, the data bring forth an intriguing possibility that phosphorylated ER␣ exists in two configurations (cis and trans). Under the regulation of Pin1, the equilibrium shifts toward the trans conformation of pS118ER␣, which is accompanied by increased transcriptional activity, presenting the possibility that the trans configuration pref-erentially places AF1 in a more active state. Recognition of the existence of multiple isoforms of ER␣ (ER␣, cis-pER␣, and transpER␣) with distinct properties and functions has implications relevant to the interpretation of phosphorylated ER␣ as a therapeutic target and biomarker, and it advances Pin1 as a significant contributing factor that could explain some of the controversies that exist with regard to the relationship between ER␣ phosphorylation and clinical outcome.
